Bolt Biotherapeutics (BOLT) Competitors $0.50 0.00 (-0.70%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrends BOLT vs. AGEN, FBIO, SABS, CRIS, MTEM, AMGN, VRTX, GILD, REGN, and ALNYShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Agenus (AGEN), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Curis (CRIS), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Agenus Fortress Biotech SAB Biotherapeutics Curis Molecular Templates Amgen Vertex Pharmaceuticals Gilead Sciences Regeneron Pharmaceuticals Alnylam Pharmaceuticals Bolt Biotherapeutics (NASDAQ:BOLT) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation, earnings and community ranking. Does the MarketBeat Community believe in BOLT or AGEN? Agenus received 387 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 69.29% of users gave Agenus an outperform vote while only 64.52% of users gave Bolt Biotherapeutics an outperform vote. CompanyUnderperformOutperformBolt BiotherapeuticsOutperform Votes8064.52% Underperform Votes4435.48% AgenusOutperform Votes46769.29% Underperform Votes20730.71% Which has more volatility and risk, BOLT or AGEN? Bolt Biotherapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Is BOLT or AGEN more profitable? Agenus has a net margin of -145.89% compared to Bolt Biotherapeutics' net margin of -665.56%. Agenus' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bolt Biotherapeutics-665.56% -69.46% -48.55% Agenus -145.89%N/A -85.68% Does the media refer more to BOLT or AGEN? In the previous week, Agenus had 3 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 3 mentions for Agenus and 0 mentions for Bolt Biotherapeutics. Agenus' average media sentiment score of 0.60 beat Bolt Biotherapeutics' score of 0.00 indicating that Agenus is being referred to more favorably in the news media. Company Overall Sentiment Bolt Biotherapeutics Neutral Agenus Positive Do insiders & institutionals believe in BOLT or AGEN? 86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 30.9% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 4.6% of Agenus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings & valuation, BOLT or AGEN? Bolt Biotherapeutics has higher earnings, but lower revenue than Agenus. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBolt Biotherapeutics$9.78M1.96-$69.20M-$1.71-0.29Agenus$160.43M0.41-$245.76M-$11.24-0.25 Do analysts prefer BOLT or AGEN? Bolt Biotherapeutics currently has a consensus price target of $3.50, suggesting a potential upside of 600.00%. Agenus has a consensus price target of $10.00, suggesting a potential upside of 253.36%. Given Bolt Biotherapeutics' higher possible upside, equities analysts clearly believe Bolt Biotherapeutics is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bolt Biotherapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Agenus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 SummaryAgenus beats Bolt Biotherapeutics on 11 of the 18 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.14M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E Ratio-0.2910.5089.8217.18Price / Sales1.96195.801,116.21116.95Price / CashN/A57.1642.8937.86Price / Book0.175.094.784.78Net Income-$69.20M$151.83M$120.23M$225.60M7 Day Performance-5.29%-2.13%-1.92%-1.23%1 Month Performance-11.79%-3.10%11.49%3.36%1 Year Performance-49.76%11.54%30.57%16.60% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics2.4727 of 5 stars$0.50-0.7%$3.50+600.0%-50.5%$19.14M$9.78M-0.29100AGENAgenus3.6855 of 5 stars$2.84-6.9%$10.00+252.1%-81.2%$66.62M$160.43M-0.27389FBIOFortress Biotech3.1454 of 5 stars$1.87-3.9%$13.67+632.8%-27.1%$51.48M$62.50M-0.63186SABSSAB Biotherapeutics2.4276 of 5 stars$3.83-6.1%$12.40+223.8%+520.0%$35.35M$2.24M0.00140Gap UpCRISCuris2.7846 of 5 stars$3.47-2.8%$23.00+562.8%-74.6%$29.38M$10.26M-0.4849MTEMMolecular Templates3.1833 of 5 stars$0.38-6.1%N/A-95.7%$2.47M$57.31M-0.1562News CoverageGap DownAMGNAmgen4.4684 of 5 stars$267.48-1.2%$319.68+19.5%-4.3%$143.78B$32.53B34.8626,700Analyst DowngradeGap UpVRTXVertex Pharmaceuticals4.7526 of 5 stars$466.43+0.6%$505.73+8.4%-0.7%$120.12B$9.87B-233.035,400Analyst ForecastAnalyst RevisionNews CoverageGILDGilead Sciences4.4898 of 5 stars$92.29+0.5%$96.43+4.5%+17.8%$115.02B$27.12B1,020.6718,000Insider TradeREGNRegeneron Pharmaceuticals4.6599 of 5 stars$724.72-0.9%$1,099.90+51.8%-16.6%$79.64B$13.12B18.1013,450Analyst ForecastALNYAlnylam Pharmaceuticals4.4132 of 5 stars$243.34-0.9%$298.09+22.5%+37.1%$31.39B$1.83B-93.682,100Analyst UpgradePositive News Related Companies and Tools Related Companies Agenus Alternatives Fortress Biotech Alternatives SAB Biotherapeutics Alternatives Curis Alternatives Molecular Templates Alternatives Amgen Alternatives Vertex Pharmaceuticals Alternatives Gilead Sciences Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BOLT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
